How Extending CVS Distribution Through 2032 At Cardinal Health (CAH) Has Changed Its Investment Story

• In October 2026, Cardinal Health announced it had entered into a binding Letter of Intent to extend its existing distribution agreement with CVS Health through June 30, 2032, maintaining the current scope of distribution services.

• This long‑dated extension reinforces the durability of Cardinal Health’s core distribution relationships, underscoring the importance of scale partnerships in its business model.

• We’ll now explore how the extended CVS distribution agreement through 2032 may influence Cardinal Health’s longer-term investment narrative and risk profile.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Cardinal Health Investment Narrative Recap

To own Cardinal Health, you need to believe its scale in pharmaceutical and medical distribution can keep attracting large, long term customers while it gradually shifts more toward higher value services. The extended CVS agreement through 2032 supports that core distribution pillar, but does not directly change the near term focus on product quality risks from the levothyroxine and Webcol recalls, or cost pressure in the Global Medical Products and Distribution segment.

The most relevant recent announcement alongside the CVS extension is Cardinal Health’s August 2026 unsecured US$4.0 billion revolving credit agreement through 2031, which refreshes its funding flexibility. While this facility itself does not alter the short term earnings drivers, it gives the company financial room to keep investing in automation, specialty distribution and at home solutions that underpin the existing growth catalysts.

But against this backdrop of a long CVS extension, investors should still be aware of emerging product quality concerns and how quickly they could…

Read the full narrative on Cardinal Health (it’s free!)

Cardinal Health’s narrative projects $297.6 billion revenue and $3.0 billion earnings by 2029. This requires 5.4% yearly revenue growth and an earnings increase of about $1.3 billion from $1.7 billion today.

Uncover how Cardinal Health’s forecasts yield a $270.94 fair value, a 19% upside to its current price.

Exploring Other Perspectives

Two Simply Wall St Community fair value estimates for Cardinal Health range widely, from about US$270.94 to US$741.95 per share, showing how far opinions can diverge. You can weigh those views against the importance of Cardinal Health’s long term distribution partnerships, such as CVS, which may influence how resilient the company’s performance could be under different business conditions.

Explore 2 other fair value estimates on Cardinal Health – why the stock might be worth over 3x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Searching For A Fresh Perspective?

The market won’t wait. These fast-moving stocks are hot now. Grab the list before they run:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include CAH.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]